Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.45 7.30 7.60 7.45 7.45 7.45 12,107 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 10

Evgen Pharma Share Discussion Threads

Showing 1526 to 1549 of 1850 messages
Chat Pages: Latest  62  61  60  59  58  57  56  55  54  53  52  51  Older
DateSubjectAuthorDiscuss
23/8/2019
19:54
Oh dear we have a troll, willywonka. In case you are not aware the next trial result is in SAH. Go and google SAH to find out what it is. They have already got a positive phase II breast cancer result so difficult to see how in the short to medium term there can be any effect of a breast cancer trial result as there isn't one ongoing! You don't half get some muppets on these threads....
nobbygnome
23/8/2019
19:07
"Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time.... This approach will maximise the commercial value of the dataset from the SAS trial."They can sell SFX-01 after the results are released, through orphan drug status.
90005nelson
23/8/2019
19:02
Nobody investing in this type of small cap company is unaware of the potential risk of eventual total capital losses in the event of complete failure as a worst case scenario. I am curious as to whether posts like yours ever have a material impact on the share price - but either way, if things go as holders hope, the rewards for the risks we take as early investors will likely be satisfactory. We shall see soon enough, for good or bad.
lovewinshatelosses
23/8/2019
18:20
This has a high risk of failure esp for breast cancer Be prepared for 70/80% drop if trials dnt go to plan
willywonka22
23/8/2019
14:23
https://twitter.com/hashtag/EVG?src=hashtag_click
ohisay
23/8/2019
14:13
Find out soon. Gla
tidy 2
23/8/2019
14:09
Game on. Been tipped here
tidy 2
16/8/2019
19:26
Phase II trial of SFX-01 in SAH scheduled for completion next month (September 2019) hxxps://clinicaltrials.gov/ct2/show/record/NCT02614742 Results will shortly follow
asat91
15/8/2019
09:19
Another use for SFX-01 would appear to be mTOR inhibition; "The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner" hTTps://www.sciencedirect.com/science/article/pii/S0944711319302284?via%3Dihub One of the authors is Dinkova who is on the scientific board of Evgen. mTOR inhibition is of interest in Cancer and Neurogenerative disease.
pdt
08/8/2019
13:06
Interesting new article on Stroke and NRF2 from University of Florida; Nrf2 Plays an Essential Role in Long-Term Brain Damage and Neuroprotection of Korean Red Ginseng in a Permanent Cerebral Ischemia Model. hTTps://www.mdpi.com/2076-3921/8/8/273/htm
pdt
06/8/2019
19:19
https://twitter.com/AIMBAGGER1/status/1158816066816098305?s=19
90005nelson
06/8/2019
18:18
Good news the other day indeed, and seems to back up those thoughts hsm12. I would have expected a more positive market reaction, but no matter - I remain long and strong, as the saying goes.
lovewinshatelosses
06/8/2019
13:49
I missed the news yesterday of further research at Kings. Clearly Kings and the British Heart Foundation (providing most of the funding) see potential in SFX-01 for Stroke. From the release; Professor Giovanni Mann, Professor of Vascular Physiology at King's College London and supervisor for the project, commented: "We are delighted to be collaborating again with Evgen Pharma and believe this project will build on our existing collaboration which showed great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complications."
pdt
31/7/2019
20:00
It's very unusual for a company hold back in releasing primary endpoint/interim results until releasing together with the final results. They would have pulled the plug if it wasn't promising.
90005nelson
31/7/2019
15:59
Absolutely not! No funding issues in foreseeable future. Stroke trial readout is a shot to nothing. I expect a big run up in the lead up to the results.
hsm12
29/7/2019
15:30
I have a small holding here and have made a couple of little top ups along the way; I agree it does seem promising and if the results are as we all hope for, great for us shareholders one hopes and more importantly great news for the potential patients it is aimed at helping. I am not trolling but genuinely interested in whether other holders think another small fund raise might be in the pipeline later this year? I am not looking to day trade or short EVG, just prepared to sit tight for several years if required and hold, potentially further adding, if news justifies further investment.
lovewinshatelosses
29/7/2019
11:42
hsm12 - as you say any hint of efficacy and the share price could multiply. What I think is interesting is that any hint of efficacy could be a read across to Stroke in general where the market opportunity is x20 that of SAH. Although in SAH you are trying to mitigate a delayed ischemia there seems some evidence that sfx-01 could assist recovery post the initial event. This is what they said in the Interims in December 2018; "In our collaboration with Professor Giovanni E. Mann at King's BHF Centre of Research Excellence, King's College London, we have also been investigating the effects of SFX-01 in an in-vivo model of ischaemic stroke. The studies include Laser Speckle Blood Flow Imaging, a technology that shows real-time blood flow around the brain, before, during and after an experimental stroke. Whilst still ongoing, the study has shown that preconditioning with SFX-01 (i.e. three days dosing prior to stroke) improves the blood flow to the site of the stroke and this results in improved measures of functional and motor deficit. Notably, both pre-treatment and acute treatment with SFX-01 after ischaemic stroke rescued blood flow on reperfusion, suggesting that SFX-01 is protective if given before a stroke. This is promising with regard to our SAS clinical trial, where SFX-01 is administered days in advance of the ischaemia that follows the initial haemorrhage." Certainly interesting times for Evgen.
pdt
26/7/2019
14:49
There does seem to be increased interest here ... expected news is still a couple of months away. I wonder if something else is brewing?
pdt
26/7/2019
14:36
Probably one of the most geared biotechs in the U.K. in terms of upside. Downside always possible but any hint of efficacy is 10X.
hsm12
25/7/2019
14:23
Big move coming in this stock.
hsm12
12/7/2019
16:07
This calendar year will be significant
dave444
24/6/2019
06:49
Excellent, the publication referred to in today's RNS is free to access, although I do not suppose it will appear in any of the best seller lists ☹️ https://www.hindawi.com/journals/omcl/2019/6218239/
timbo003
13/6/2019
19:30
I don't think there was anything new in those results. I see Finncap maintain their short term target price at 35p rising to 85p on a successful outcome from the SAH trial. Just have to wait patiently for 3 or 4 months.
pdt
12/6/2019
11:55
I have been eating sprout from Abel & Cole and also tried the shots of juice from Tonic Attack. The website of the latter shows that a lot of thought has gone into the production of the juice to result in a high quality product. I am probably going to continue to take both. The juice tastes exactly as you can imagine crushed sprout to taste like! The fresh sprout goes well added to a lunchtime sandwich or with a salad! I wonder if we will get any new news with tomorrow's results? There does seem to be more interest in the shares over the last couple of days.
pdt
Chat Pages: Latest  62  61  60  59  58  57  56  55  54  53  52  51  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191209 20:35:32